Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States

Abstract

Background: Patients with polycythemia vera (PV) often experience symptoms that adversely affect their quality of life (QoL). The ongoing, prospective, observational REVEAL (Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices) study was designed to collect contemporary data regarding burden of disease, clinical management, patient-reported outcomes (PROs), and health care resource utilization from adult patients with PV in the United States.

Patients and methods: Data on PROs were collected at enrollment using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS; range, 0-100); the European Organization for Research and Treatment of Cancer-Core Quality of Life Questionnaire, version 3.0 (EORTC QLQ-C30; range, 0-100); and the Work Productivity and Activity Impairment Questionnaire-Specific Health Problem (WPAI-SHP; range, 0%-100%).

Results: Among 2309 patients, mean (SD) disease duration was 5.8 (6.1) years and Charlson Comorbidity Index was 3.4 (0.8); 54.0% (1247/2309) were male. Mean (SD) MPN-SAF TSS was 18.8 (15.5). The most common symptoms were fatigue (80.1% [1844/2302]), early satiety (60.9% [1402/2302]), and inactivity (57.6% [1324/2302]). The most common severe symptoms were fatigue (16.8% [387/2302]), itching (13.4% [308/2302]), and inactivity (11.8% [271/2302]). The mean (SD) EORTC QLQ-C30 global health status/QoL score was 73.1 (23.2): mean functional subscale scores ranged from 80.5 (23.9) for cognitive functioning to 85.7 (24.6) for social functioning. The mean WPAI-SHP activity impairment score was 19.7% (n = 2300). Employed patients had mean WPAI-SHP scores for absenteeism, presenteeism, and overall work impairment of 3.2% (n = 810), 12.1% (n = 807), and 13.4% (n = 802), respectively.

Conclusion: These data confirm that many patients with PV experience symptoms, QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL will be important for evaluating how PROs change over time in these patients.

Trial registration: ClinicalTrials.gov NCT02252159.

Keywords: Activity impairment; Myeloproliferative neoplasm; Quality of life; Symptoms; Work productivity.

Figure 1.. Myeloproliferative Neoplasm Symptom Assessment From (MPN-SAF) Sympton Severity at Enrollment. ^aWeight Loss Indicate Unintentional Weight Loss in the Past 6 Months

^aEach item was scored on a scale from 0 (absent) to 10 (worst imaginable). Only evaluable patients with MPN-SAF data (n = 2302) were included.

Figure 2. Mean (SD) Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Symptom Scores at Enrollment^a

^a Each item was scored on a scale from 0 (absent) to 10 (worst imaginable). Only evaluable patients with MPN-SAF data (n = 2302) were included. ^b Unintentional weight loss in the past 6 months.

Figure 3. Mean European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire (EORTC QLQ-C30) Scores for (A) Symptom Subscales and (B) QoL and Functional Subscales at Enrollment^a

Abbreviation: QoL, quality of life. ^a All scores were standardized using linear transformation to 0 to 100. Only evaluable patients with EORTC QLQ-C30 data (n = 2298–2304 for each score) were included.

Figure 4. Mean Work Productivity and Activity Impairment Questionnaire—Specific Health Problem Scores at Enrollment^a

Abbreviation: PV polycythemia vera. ^a All items on the basis of 7-day recall (ie, regarding work/activity during the 7 days preceding the survey).